AR and posterior cortical atrophy: As patient genetic testing becomes more popular and investigators branch into targeted combination therapies, a compilation of the genetic alterations present in actionable dysregulated pathways within five common PCa cell lines (AR-expressing: LNCaP, VCaP, 22Rv1; AR-null/castration-resistant: PC-3 and Du-145) and three daughter cell lines that are castration-resistant (LNCaP-95, LNCaP-abl, and VCaP-CR) will allow for strategic in vitro investigation of the relationship between genetic alterations, targeted therapies, and known PCa mechanisms.